NCT00003963 - Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 1999

Primary Completion Date

September 30, 2003

Study Completion Date

February 28, 2005

Conditions

Lymphoma

Interventions

BIOLOGICAL

rituximab

Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Week 5-8: Rituxan given every 2 weeks. Week 9-12: Schedule same as week 5-8.

DRUG

vinorelbine ditartrate

"Week 1-4: Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Vinorelbine given weekly x3, with one week off. Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."

Trial Locations (1)

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles